NL-OMON26770招募中不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients.
VU Medical Center0 个研究点目标入组 225 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 225
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1. Patients with advanced (unresectable and/or metastatic) renal cell cancer;
- •2. Patients who will start treatment with sunitinib, pazopanib, sorafenib, axitinib or everolimus;
排除标准
- •1. Clinical findings associated with an unacceptably high tumor biopsy risk, according to the judgement of the investigator;
- •2. Radiotherapy on target lesions during study or within 4 weeks of the start of study drug;
研究者
相似试验
进行中（未招募）
不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patientsEUCTR2011-006009-85-NLVU University medical center225
已完成
不适用
Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patientskidney cancerRenal cell cancer10038364NL-OMON37502Vrije Universiteit Medisch Centrum225
终止
不适用
Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer PatientsRenal Cell CancerNCT02071719M. Labots6
已完成
不适用
Tumor Kinase Inhibitor Concentrations Measured by PETDisseminated Malignant NeoplasmNCT02111889Amsterdam UMC, location VUmc8
已完成
不适用
Identification of PAthways of Kinase Inhibitors TOxicityKinase Inhibitors ToxicityNCT03896139Groupe Hospitalier Pitie-Salpetriere4,000